QUANTGENE careers

Quantgene accurately detects the 10 deadliest cancers at early stages in standard blood samples.

In an initial clinical study across 12 colorectal cancer patients the Quantgene platform detects 9 out of 10 cancer patients correctly at a 100% specificity, far above any existing method. 9 additional cancer trials are in the pipeline. The technology was developed by a team of leading scientists with backgrounds across Memorial Sloan Kettering CC (the world’s leading cancer research center), UC Berkeley, Stanford University, Geneva University and Google Life Sciences. The non-invasive laboratory blood test can be deployed at a cost below $200 per screening compared to currently ~$10,000 for less accurate experimental approaches. To date, no universal cancer screening is available and 450,000 Americans lives could be saved each year.